Skip to main content

Table 1 Number of registered patients for population 1 by the treatment group and overall registration rate for each participating hospital

From: CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan

Hospital

Number of HA and KA procedures performed (2018)

Insurance status

Initial treatment allocation

Crossover achieved

LMWH group (population 1)

Aspirin group

(population 1)

Overall registration rate (combined for both groups)

1

    

n

n

%

2

    

n

n

%

3

    

n

n

%

4

    

n

n

%

5

    

n

n

%

6

    

n

n

%

7

    

n

n

%

8

    

n

n

%

9

    

n

n

%

10

    

n

n

%

11

    

n

n

%

12

    

n

n

%

13

    

n

n

%

14

    

n

n

%

15

    

n

n

%

16

    

n

n

%

17

    

n

n

%

18

    

n

n

%

19

    

n

n

%

20

    

n

n

%

21

    

n

n

%

22

    

n

n

%

23

    

n

n

%

24

    

n

n

%

25

    

n

n

%

26

    

n

n

%

27

    

n

n

%

28

    

n

n

%

29

    

n

n

%

30

    

n

n

%

31

    

n

n

%

Total

    

n

n

%

  1. Population 1 refers to registered patients undergoing primary THA or TKA for a diagnosis of OA, who are eligible to receive the study drug
Back to article page

Trials

ISSN: 1745-6215